Microbial Ecosystem Therapeutics

NuBiyota is a clinical-stage biotechnology company focused on developing next-generation microbial ecosystem therapeutics to restore gut health and treat chronic diseases. The company's proprietary MET platform, originally developed at the University of Guelph, utilizes complex, defined consortia of live bacteria derived from healthy donors and manufactured under stringent anaerobic conditions. Their lead candidates, MET-1 and MET-2, are designed to provide a safer and more standardized alternative to traditional fecal microbiota transplants (FMT). NuBiyota is currently advancing its pipeline through clinical trials for indications including recurrent Clostridioides difficile infection, inflammatory bowel disease, and complications arising from cancer immunotherapy.